



Mechanistic Insights of Selective Autophagy in Neurodegenerative Diseases

Guest Editors:

Dr. Ashok Iyaswamy

Centre for Parkinson's Disease
Research, School of Chinese
Medicine, Hong Kong Baptist
University, Hong Kong

Dr. Chun Kit Benjamin Tong

Centre for Parkinson's Disease
Research, School of Chinese
Medicine, Hong Kong Baptist
University, Hong Kong

**Dr. Sreenivasmurthy Sravan
Gopalkrishnashetty**

Department of Neurology,
University of Texas Medical
Branch, Galveston, TX, USA

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editors

Selectively targeting cytosolic components or organelles for degradation is a major surveillance mechanism employed in several cell types and animal models. Damaged organelles and protein aggregates are crucial hallmarks of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and so on. In this process, several selective autophagy receptors bind to the dysregulated cellular cargo via the Atg8/LC3/GABARAP proteins and promote their degradation. Modulating quality control mechanisms can alleviate the devastating effects of neurodegenerative diseases.

This Special Issue will focus on recent advances in selective autophagy in neurodegenerative diseases, aiming to foster an improved understanding of the roles of selective autophagy in the pathogenesis, propagation, and therapeutics of various neurodegenerative diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)